Supreme Court Accepts Case That Could Shape Field Of Personalized MedicineBloomberg: Diagnostic Medical Test Patents Draw High Court Scrutiny
The U.S. Supreme Court, accepting a case that will shape the burgeoning business of personalized medicine, agreed to consider what types of diagnostic medical tests can be patented. The justices agreed today to hear an appeal from the Mayo Clinic, which is challenging a lower court decision backing two patents for determining the dosage of medicines to treat stomach diseases. The ruling cleared the patents' owner, Prometheus Laboratories Inc., to press an infringement suit against two Mayo units. Patent protection is important for companies that are focusing on personalized medicine, including Myriad Genetics Inc. (MYGN) and Novartis AG. (NVS) The field involves determining whether a patient is genetically susceptible to a particular disease or would be especially responsive to certain medicines (Stohr and Decker, 6/20). This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.